Welcome to Action Kidney Cancer

Action Kidney Cancer ·
@ACTION4KC

The first adjuvant treatment pembrolizumab has been approved for people with increased risk of their #kidneycancer returning after surgery in England and Wales on the NHS, by the National Institute for Health and Care Excellence
Read about the therapy:
https://t.co/iJpfD3zH8E https://t.co/Kc0Bp52mDt

View on Twitter

4

Action Kidney Cancer ·
@ACTION4KC

Health and Social Care Secretary and Deputy Prime Minister, Thérèse Coffey sets out a plan for patients with new funding to bolster social care over the winter.
Read more on our website here: https://t.co/fEddu4ZGzD https://t.co/EOgAyxf6Qs

View on Twitter

Action Kidney Cancer ·
@ACTION4KC

Now open! Along with @IKCCorg we have launched the 2022 Global Patient Survey! All #kidneycancer patients and carers are invited to share their experiences and insights in the online survey.
Find more on our website: https://t.co/tq5uNlvIZv https://t.co/sOiPQtzulE

View on Twitter

Action Kidney Cancer ·
@ACTION4KC

This phase 2 CANTATA study compared telaglenastat plus cabozantinib with placebo plus cabozantinib in previously treated patients with clear-cell metastatic #kidneycancer.
To read about the study and outcomes:
https://t.co/redBIjPqCj

#bypatientsforpatients https://t.co/SdzXFMtTXG

View on Twitter

0

Action Kidney Cancer ·
@ACTION4KC

In this phase 3, randomised study the immune system was stimulated with nivolumab before surgery followed by nivolumab after surgery in patients with high risk localised #kidneycancer. This was compared to surgery alone.
Read more: https://t.co/UbKgXJG63X https://t.co/9VPeG0hDTY

View on Twitter

0

Follow on Twitter

Facebook

Action Kidney Cancer

This study looked at levels of a biomarker called C-reactive protein (CRP) in the blood to try to predict the effectiveness of a combination of avelumab plus axitinib in people with advanced kidney cancer.

Read more on our website here:https://actionkidneycancer.org/c-reactive-protein-as-a-potential-biomarker-of-effectiveness-of-avelumab-plus-axitinib-in-people-with-advanced-kidney-cancer/

A biomarker is a biological

Now open! Action Kidney Cancer and @IKCCorg have launched the 2022 Global Patient Survey! All #kidneycancer patients and carers are invited to share their experiences and insights in the online survey.
Find out more on our website: https://actionkidneycancer.org/.../2022-ikcc-global.../

#kidneycancer #bypatientsforpatients #StrongerTogether

Now open! Action Kidney Cancer and @IKCCorg have launched the 2022 Global Patient Survey! All #kidneycancer patients and carers are invited to share their experiences and insights in the online survey.
Find our more on our website: https://actionkidneycancer.org/.../2022-ikcc-global.../

Health and Social Care Secretary and Deputy Prime Minister, Thérèse Coffey sets out a plan for patients with new funding to bolster social care over the winter.
Read more on our website here: https://actionkidneycancer.org/governments-new-health-and-social-care-plan/

Health and Social Care Secretary and Deputy Prime Minister, Thérèse Coffey sets out a plan for patients with new funding to bolster social care over the winter: She will set out an expectation that anyone who needs an appointment should get one at a GP practice within two weeks – and patients wi...

Now open! Action Kidney Cancer and @IKCCorg have launched the 2022 Global Patient Survey! All #kidneycancer patients and carers are invited to share their experiences and insights in the online survey.
Find our more on our website: https://actionkidneycancer.org/get-involved/2022-ikcc-global-patient-survey/

Late last week we learnt that the National Institute for Health and Care Excellence (NICE) approved pembrolizumab for the adjuvant treatment of people with increased risk of their kidney cancer returning after surgery (nephrectomy). This is the first adjuvant immunotherapy to be approved for use on the NHS in England and Wales.
Read more on our website here: https://actionkidneycancer.org/adjuvant-pembrolizumab-approved-by-nice/

Late last week we learnt that the National Institute for Health and Care Excellence (NICE) approved pembrolizumab for the adjuvant treatment of people with increased risk of their kidney cancer returning after surgery (nephrectomy). This is the first adjuvant immunotherapy to be approved for use on....